Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Blood (2018) 132 (Supplement 1): 4020.

https://doi.org/10.1182/blood-2018-99-117310

Published: 2018

Journal Articles

Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia

Seemana Bhattacharya, PhD, Sujan Piya, PhD, Qi Zhang, PhD, Natalia Baran, PhD MD, Teresa McQueen, MS, R. Eric Davis, MD, Nicholas Cosford, PhD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 3934.

https://doi.org/10.1182/blood-2018-99-114817

Published: 2018

Journal Articles

Adoptive T-Cell Therapy with TCL1-Specific TCR for B-Cell Lymphomas

Jinsheng Weng, MD PhD, Kelsey Moriarty, BD, Yong Pan, Man Chun John MA, PhD, Rohit Mathur, PhD, Zheng Zhang, Hiroki Torikai, MD, Sourindra N Maiti, Fuliang Chu, PhD, Xiaoyun Cheng, Swathi Karri, Deepshika Medapalli, Laurence J N Cooper, MD PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD

Blood (2018) 132 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2018-99-115424

Published: 2018

Journal Articles

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Sujan Piya, PhD, Seemana Bhattacharya, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Natalia Baran, PhDMD, Teresa McQueen, MS, R. Eric Davis, MD, Yimin Qian, PhD, Kanak Raina, PhD, M. James You, MD PhD, Marina Y. Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 890.

https://doi.org/10.1182/blood-2018-99-115692

Published: 2018

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 447.

https://doi.org/10.1182/blood-2018-99-113721

Published: 2018

Journal Articles

CD200 Is a Stem Cell-Specific Immunosuppressive Target in AML

Shelley Herbrich, MS, Keith Baggerly, PhD, Gheath Alatrash, DO, PhD, R. Eric Davis, MD, Michael Andreeff, MD PhD, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 2768.

https://doi.org/10.1182/blood-2018-99-114818

Published: 2018

Journal Articles

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R 2 ) in Previously Untreated Follicular Lymphoma

Nathan H. Fowler, MD, Preetesh Jain, MBBS,MDDM,PhD, Loretta J. Nastoupil, MD, F. B. Hagemeister, MD, Sheryl G Forbes, Lore Lagrone, Luis Fayad, MD, Hun Ju Lee, MD, R. Eric Davis, MD, Jason R. Westin, MD, Michael Wang, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD

Blood (2018) 132 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2018-99-119592

Published: 2018

Journal Articles

Inhibition of Translation Initiation and Heat Shock Factor 1 (HSF1): A Novel Strategy Targeting FLT3 Double Mutant and Non-FLT3 Mutant AML Progenitor/Stem Cells

Jo Ishizawa, MD PhD, Ran Zhao, Lauren Heese, Alex Jaeger, PhD, Yuki Nishida, Rodrigo Jacamo, PhD, Kensuke Kojima, MD PhD, Man Chun John MA, PhD, Vivian Ruvolo, PhD, Dhruv Chachad, R. Eric Davis, MD, William Devine, PhD, John A Porco, Jr., PhD, Luke Whitesell, MD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2637.

https://doi.org/10.1182/blood.V130.Suppl_1.2637.2637

Published: 2017

Journal Articles

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

Jason R. Westin, MD, Yasuhiro Oki, MD, Loretta Nastoupil, MD, Luis Fayad, MD, Sattva S. Neelapu, MD, Francesco Turturro, MD, F. B. Hagemeister, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, MD, Ken H. Young, MD PhD, Timothy J. McDonnell, MD PhD, Richard J. Ford, MD PhD, R. Eric Davis, MD

Blood (2017) 130 (Supplement 1): 189.

https://doi.org/10.1182/blood.V130.Suppl_1.189.189

Published: 2017

Journal Articles

High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study

Loretta Nastoupil, MD, Jason R. Westin, MD, Nathan H. Fowler, MD, Michelle A. Fanale, MD, Felipe Samaniego, MD, Yasuhiro Oki, MD, Ly Dsouza, PA-C, Chizobam Obi, RN, JingJing Cao, Xiaoyun Cheng, Man Chun John MA, PhD, Wang Zhiqiang, Lei Feng, MS, Shouhao Zhou, R. Eric Davis, MD, Sattva S. Neelapu, MD

Blood (2017) 130 (Supplement 1): 414.

https://doi.org/10.1182/blood.V130.Suppl_1.414.414

Published: 2017

Journal Articles

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Melody R Becnel, MD, Loretta Nastoupil, MD, R. Eric Davis, MD, F. B. Hagemeister, MD, Michelle A. Fanale, MD, Luis Fayad, MD, Jason R. Westin, MD, Michael Wang, BS, Yasuhiro Oki, MD, Linda Claret, Sheryl G Forbes, Lei Feng, MS, Felipe Samaniego, MD, Sattva S. Neelapu, MD, Nathan Fowler, MD

Blood (2017) 130 (Supplement 1): 4040.

https://doi.org/10.1182/blood.V130.Suppl_1.4040.4040

Published: 2017

Journal Articles

B-Cell Maturation Antigen (BCMA)-Specific, Centyrin TM -Based, PiggyBac TM -Transposed CAR-T Memory Stem Cells Are Effective Against p53 -/- and Patient-Derived Multiple Myeloma Tumors

Blood (2017) 130 (Supplement 1): 3068.

https://doi.org/10.1182/blood.V130.Suppl_1.3068.3068

Published: 2017

Journal Articles

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Elisabet E. Manasanch, MD, Rohit Mathur, PhD, Hans C. Lee, MD, Donna M. Weber, MD, Krina K. Patel, MDMSc, Sheeba K. Thomas, MD, Silvia C. Munoz, RN, Claudia Morales de Partovi, Catherine M. Claussen, MS, Pei Lin, MDDM,MDC, Behrang Amini, MD, Linghua Wang, Man Chun John MA, PhD, Yun Qing, Feng Lei, MS, Veera Baladandayuthapani, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Robert Z. Orlowski, MD PhD

Blood (2017) 130 (Supplement 1): 3089.

https://doi.org/10.1182/blood.V130.Suppl_1.3089.3089

Published: 2017

Journal Articles

Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma

Rohit Mathur, PhD, Zheng Zhang, Jin He, Roman Galetto, PhD, Agnès Gouble, PhD, Isabelle Chion-Sotinel, Stéphanie Filipe, PhD, Annabelle Gariboldi, Tanooha Veeramachaneni, Elisabet E. Manasanch, MD, Sheeba K. Thomas, MD, Hans C. Lee, MD, Krina K. Patel, MDMSc, Donna M. Weber, MD, R. Eric Davis, MD, Robert J. Orlowski, MD PhD, Julianne Smith, PhD, Jing Yang, PhD, Sattva S. Neelapu, MD

Blood (2017) 130 (Supplement 1): 502.

https://doi.org/10.1182/blood.V130.Suppl_1.502.502

Published: 2017

Journal Articles

Noninvasive Detection of BCL2 , BCL6 , and MYC Translocations in Diffuse Large B-Cell Lymphoma

Blood (2016) 128 (22): 2930.

https://doi.org/10.1182/blood.V128.22.2930.2930

Published: 2016

Journal Articles

Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b

Jo Ishizawa, MD PhD, Kenji Nakamaru, Takahiko Seki, Koichi Tazaki, Kensuke Kojima, MD PhD, Dhruv Chachad, Courtney D DiNardo, MD, Sherry Pierce, BSN, BA, Keyur P. Patel, MD PhD, Archie Tse, R Eric Davis, MD, Arvind Rao, PhD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 2893.

https://doi.org/10.1182/blood.V128.22.2893.2893

Published: 2016

Journal Articles

Felipe Samaniego

Neeraj Jain, PhD, Lalit Sehgal, PhD, R. Eric Davis, MD, Stephen Joseph Shuttleworth, PhD, Felipe Samaniego, MD

Blood (2016) 128 (22): 5145.

https://doi.org/10.1182/blood.V128.22.5145.5145

Published: 2016

Journal Articles

Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Blood (2015) 126 (23): 2705.

https://doi.org/10.1182/blood.V126.23.2705.2705

Published: 2015

Journal Articles

B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma: Tonic Alone in the Germinal Center B-Cell Subtype, Plus Self Antigen-Induced in the Activated B-Cell Subtype

Ondrej Havranek, MDPhD, Stefan Koehrer, MD, Jingda Xu, PhD, Lisa Becker, Justin M Comer, Anusha R Karri, Zhiqiang Wang, PhD, Wencai Ma, PhD, Jason R Westin, MD, Tomasz Zal, PhD, Jan A Burger, MD PhD, R Eric Davis, MD

Blood (2015) 126 (23): 464.

https://doi.org/10.1182/blood.V126.23.464.464

Published: 2015

NARROW

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia

Adoptive T-Cell Therapy with TCL1-Specific TCR for B-Cell Lymphomas

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

CD200 Is a Stem Cell-Specific Immunosuppressive Target in AML

Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R 2 ) in Previously Untreated Follicular Lymphoma

Inhibition of Translation Initiation and Heat Shock Factor 1 (HSF1): A Novel Strategy Targeting FLT3 Double Mutant and Non-FLT3 Mutant AML Progenitor/Stem Cells

Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results

High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

B-Cell Maturation Antigen (BCMA)-Specific, Centyrin TM -Based, PiggyBac TM -Transposed CAR-T Memory Stem Cells Are Effective Against p53 -/- and Patient-Derived Multiple Myeloma Tumors

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma

Noninvasive Detection of BCL2 , BCL6 , and MYC Translocations in Diffuse Large B-Cell Lymphoma

Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b

Felipe Samaniego

Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia

Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma: Tonic Alone in the Germinal Center B-Cell Subtype, Plus Self Antigen-Induced in the Activated B-Cell Subtype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only